Biogen stock slides 2% after it withdraws authorization application with EU regulatorMarket Watch • 04/22/22
Medicare Will Limit Coverage of Biogen's Alzheimer's Drug to Those in Clinical TrialsBarrons • 04/08/22
BIIB FINAL DEADLINE: Hagens Berman, National Trial Attorneys, Alerts Biogen Inc. (BIIB) Investors to Tomorrow's Lead Plaintiff DeadlineNewsfile Corp • 04/07/22
BIIB 8-DAY INVESTOR DEADLINE: Hagens Berman, National Trial Attorneys, Reminds Biogen Inc. (BIIB) Investors of April 8th Lead Plaintiff Deadline, Encourages Investors with Losses to Contact Firm's AttorneysNewsfile Corp • 04/05/22
New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease ProgressionGlobeNewsWire • 04/04/22
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDAGlobeNewsWire • 03/30/22